Top Rituximab Brands Revolutionizing Treatment Options

Rituximab, a monoclonal antibody used primarily in the treatment of certain autoimmune diseases and types of cancer, has gained considerable prominence in the medical field. With several pharmaceutical companies manufacturing it, patients and healthcare providers often look for the most reputable brands to ensure efficacy and safety. Brands like Rituxan, manufactured by Genentech in collaboration with Biogen, and Truxima, by Celltrion, have built strong reputations based on rigorous scientific development and testing. To explore a comprehensive list of trusted brands offering rituximab, continue reading below.

Illustration of rituximab

Best brands of rituximab in 2025

Roche

Roche's Rituxan (rituximab) is a leading monoclonal antibody therapy, widely used for treating B cell malignancies and autoimmune diseases. It has demonstrated significant efficacy, with phase III studies showing improved outcomes in patients with rheumatoid arthritis and non-Hodgkin's lymphoma. The drug has a substantial market presence, with sales contributing to Roche's overall growth, such as the company's 6% increase in core earnings per share in 2023 partly driven by strong sales of its key medicines, including Rituxan. The Rituxan market is expected to grow at a CAGR of around 16% from 2023 to 2030, reflecting its continued importance in the therapeutic landscape. Despite the upcoming expiration of its patent, Rituxan remains a cornerstone in Roche's portfolio.

Biogen Idec

Biogen Idec, in collaboration with Roche, is a leading producer of rituximab, a monoclonal antibody utilized in treating various conditions, such as lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia. In 2009, RITUXAN generated revenues of $1.1 billion from their unconsolidated joint business arrangement, experiencing a 3% decrease due to the expiration of royalties on sales outside the U.S. The drug has demonstrated significant efficacy, exemplified in the MinT study where 81% of patients receiving RITUXAN alongside chemotherapy did not experience treatment failure at two years, compared to 58% with chemotherapy alone. Biogen Idec's share of co-promotion profits for RITUXAN initially stood at 40% but adjusted to 35% after GA101 reached specific sales milestones. This collaboration has been pivotal in advancing the treatment of serious medical conditions. For more information, visit Biogen Idec's official news release.

Sandoz

Sandoz is a leading producer of rituximab biosimilars, with its products Rixathon and Riximyo approved by the European Commission in 2017 for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and immunological diseases like rheumatoid arthritis. These biosimilars have demonstrated comparable quality, safety, and efficacy to the reference product Mabthera. Rixathon and Riximyo are available in 500-mg and 100-mg concentrations and have been integral in expanding biosimilar market share, with rituximab biosimilars accounting for 73% of the market as of Q3 2023. Sandoz's rapid infusion application for rituximab biosimilars reduces infusion time to 90 minutes, compared to 3-4 hours for the reference medicine. This advancement has significantly improved treatment convenience for cancer patients.

Pfizer

Pfizer's RUXIENCE (rituximab-pvvr) is a leading biosimilar in the rituximab market, having gained FDA approval in July 2019 for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and specific autoimmune conditions. By Q3 2022, RUXIENCE established itself as the market leader within the rituximab biosimilar segment, with biosimilars overall commanding a 73% market share as of Q4 2023. The average sales price (ASP) of RUXIENCE and other biosimilars has seen a remarkable 70% decrease, leading to increased accessibility and affordability of these essential treatments by Q1 2024. RUXIENCE is Pfizer's third FDA-approved oncology biosimilar from 2019, underscoring the company's dedication to providing cost-effective and high-quality healthcare solutions. For more details on the FDA approval of RUXIENCE, visit the official Pfizer press release.

Teva Pharmaceuticals

Teva Pharmaceuticals, in partnership with Celltrion Healthcare, has established itself as a leading producer of the rituximab biosimilar Truxima, which is the only biosimilar to Roche's Rituxan available in the United States for treating rheumatoid arthritis. Truxima has gained significant market share, reaching 46% in major European countries like the UK, France, Italy, Germany, and Spain, and 27.6% in the US as of the third quarter of 2022. It was approved by the US FDA in November 2018 and has been available in the US since May 2020. Truxima is also used to treat non-Hodgkin's lymphoma, granulomatosis with polyangiitis, and microscopic polyangiitis. The drug has demonstrated a similar safety profile and high response rate to the original Rituxan in post-marketing studies.

Celltrion Healthcare

Celltrion Healthcare's Truxima (CT-P10) is a leading rituximab biosimilar, approved by the European Medicines Agency in 2017 and the US FDA in 2018, demonstrating high clinical effectiveness in treating non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Truxima has achieved a significant market share, reaching 46% in major European countries like the UK, France, Italy, Germany, and Spain, and 40.2% across all European countries. Real-world data shows that 74% of patients achieved a complete response and 22% a partial response over a 6-month observation period. The biosimilar has also shown a similar infusion-related reaction (IRR) rate to the reference product, with only 10% of patients reporting IRRs, mostly grade 1 or 2. This makes Truxima a cost-effective and reliable treatment option. For more information, visit their official announcement.

Mylan

Mylan, now part of Viatris and in partnership with Biocon, is a leading producer of rituximab biosimilars, with plans to launch these products in Europe, as announced in their quarterly earnings call. The global rituximab biosimilars market, where Mylan is a key player, reached a value of nearly $1.602 billion in 2020 and is expected to grow to $3.474 billion by 2025 at a CAGR of 16.7%. Mylan's biosimilars pipeline includes rituximab and etanercept, with a strong focus on European markets. North America, led by the USA, accounts for a significant portion of the rituximab biosimilars market, with Mylan being one of the top competitors. The market's growth is driven by factors such as government initiatives, increased healthcare expenditure, and the low cost of biosimilars. For detailed updates on Mylan's pipeline and biosimilar developments, follow the latest news and insights.

Amgen

Amgen, through its partnership with Allergan (now AbbVie), has established itself as a leading producer of rituximab biosimilars, notably with its product RIABNI (rituximab-arrx). RIABNI has received FDA approval for treating various conditions, including Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and moderate to severely active rheumatoid arthritis. As of Q1 2024, the biosimilar share of the rituximab market has reached 75%, with RIABNI contributing to this significant market penetration. The rituximab biosimilars market is expected to grow at a 12.0% CAGR from 2024 to 2031, driven by increasing demand and technological advancements. Amgen's biosimilar offerings have been instrumental in reducing healthcare costs and expanding patient access to critical treatments.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a leading producer of rituximab, having launched the first biosimilar rituximab, Reditux™, in 2007, which marked a significant milestone in the biosimilars market. The company has a strong presence in the global pharmaceutical industry, with a vertically integrated organization and modern infrastructure. Dr. Reddy's has demonstrated industry-leading product development skills and an early mover advantage in biosimilars. Their rituximab biosimilar has shown positive treatment outcomes and high retention rates, contributing to the market growth expected to reach $4.89 billion by 2028 with a CAGR of 12.8%. You can find more detailed information about Dr. Reddy's innovative approaches and achievements in their 2016 presentation.

Hetero Drugs

Hetero Drugs is a leading producer of rituximab biosimilars, known for its state-of-the-art single-use manufacturing facilities and a dedicated R&D wing that meets US FDA and EU standards. The company has successfully launched rituximab globally, along with other biosimilars like Darbapoetin alfa, Bevacizumab, and Adalimumab. Hetero's significant contribution includes being among the largest suppliers of Remdesivir, with around 50-60% of global production capacity, and achieving a business growth of approximately 25% in the financial year 2020-21 despite challenging circumstances. The company's biosimilars segment is part of its robust portfolio, which also includes APIs, branded generics, and custom pharmaceutical services. Hetero's commitment to sustainability and innovation has positioned it as a key player in the global biosimilars market.